Details
Stereochemistry | MIXED |
Molecular Formula | C29H31N7O3 |
Molecular Weight | 525.6026 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(COc1cc(-c2ccc(nc2)N3CC4CC(C3)N4Cc5ccc(nc5)OC)c6c(C#N)cnn6c1)O
InChI
InChIKey=XIIOFHFUYBLOLW-UHFFFAOYSA-N
InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07949 Gene ID: 5979.0 Gene Symbol: RET Target Organism: Homo sapiens (Human) |
0.56 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RETEVMO Approved UseRETEVMO is a kinase inhibitor indicated for the treatment of: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)1. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) |
|||
Primary | RETEVMO Approved UseRETEVMO is a kinase inhibitor indicated for the treatment of: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)1. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) |
|||
Primary | RETEVMO Approved UseRETEVMO is a kinase inhibitor indicated for the treatment of: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)1. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
675218
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/18/2071
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
||
|
FDA ORPHAN DRUG |
653118
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
||
|
FDA ORPHAN DRUG |
652318
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
134436906
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
PRIMARY | |||
|
C134987
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
PRIMARY | |||
|
DB15685
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
PRIMARY | |||
|
10967
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
PRIMARY | |||
|
Selpercatinib
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
PRIMARY | |||
|
CEGM9YBNGD
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
PRIMARY | |||
|
2152628-33-4
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
PRIMARY | |||
|
2370147
Created by
admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
|
PRIMARY |
ACTIVE MOIETY